Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377029262> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4377029262 endingPage "A10" @default.
- W4377029262 startingPage "A10.2" @default.
- W4377029262 abstract "Introduction Mucopolysaccharidoses (MPS), comprise a group of rare chronically debilitating metabolic diseases and associated with reduced life expectancy and a substantial unmet clinical need. Current research directs towards a number of new treatment targets and strategies. Individual treatment trials (ITT) could make these options rapidly available to patients. Based on scientific publication, this is hardly used. We assess the utilization of and relevant barriers to ITT in MPS as well as potential solutions. Methods Phase 1 was done with 5 international top experts. After this interim analysis, the survey will be rolled out to a broader group of experts. Results Five MPS experts from Austria, Brazil, Germany and Italy have been enrolled. In total these clinicians manage about 350 MPS patients. Only three experts ever ran 1–3 numbers of ITT in MPS patients, solely MPS type II (n=2) and VI (n=1), summing up to a total of five ITTs, which is about 1.4% of their patients. The treatments used in ITTs comprise Montelukast, THC, Curcuma and a viral vector with transgene. As barriers for a wider use of ITTs, the im-practicability for implementation (n=1) and the insufficient training in ITT (n=1) have been indicated. All experts consider it highly likely that a decision analysis tool increases the use of ITT in MPS. Conclusions ITT are used in about 1% of MPS patients. This seems extremely low, considering the commonness of off label use in children with severe conditions, the high unmet medical need in MPS and the number of research results, which indicate various promising repurposing strategies. This interim analysis already demonstrates several relevant barriers and high potential of the planned decision framework tool to overcome this." @default.
- W4377029262 created "2023-05-19" @default.
- W4377029262 creator A5002597500 @default.
- W4377029262 creator A5015179904 @default.
- W4377029262 creator A5059494159 @default.
- W4377029262 creator A5079734090 @default.
- W4377029262 creator A5079918919 @default.
- W4377029262 creator A5089564343 @default.
- W4377029262 date "2023-05-18" @default.
- W4377029262 modified "2023-09-28" @default.
- W4377029262 title "30 Utilization of and barriers to individual treatment trials in mucopolysaccharidosis – interim results of an expert survey" @default.
- W4377029262 doi "https://doi.org/10.1136/archdischild-2023-esdppp.30" @default.
- W4377029262 hasPublicationYear "2023" @default.
- W4377029262 type Work @default.
- W4377029262 citedByCount "0" @default.
- W4377029262 crossrefType "journal-article" @default.
- W4377029262 hasAuthorship W4377029262A5002597500 @default.
- W4377029262 hasAuthorship W4377029262A5015179904 @default.
- W4377029262 hasAuthorship W4377029262A5059494159 @default.
- W4377029262 hasAuthorship W4377029262A5079734090 @default.
- W4377029262 hasAuthorship W4377029262A5079918919 @default.
- W4377029262 hasAuthorship W4377029262A5089564343 @default.
- W4377029262 hasBestOaLocation W43770292621 @default.
- W4377029262 hasConcept C126322002 @default.
- W4377029262 hasConcept C166957645 @default.
- W4377029262 hasConcept C177713679 @default.
- W4377029262 hasConcept C187212893 @default.
- W4377029262 hasConcept C2776957806 @default.
- W4377029262 hasConcept C2779134260 @default.
- W4377029262 hasConcept C2779416428 @default.
- W4377029262 hasConcept C2779969927 @default.
- W4377029262 hasConcept C2910638406 @default.
- W4377029262 hasConcept C512399662 @default.
- W4377029262 hasConcept C535046627 @default.
- W4377029262 hasConcept C61943457 @default.
- W4377029262 hasConcept C71924100 @default.
- W4377029262 hasConcept C95457728 @default.
- W4377029262 hasConceptScore W4377029262C126322002 @default.
- W4377029262 hasConceptScore W4377029262C166957645 @default.
- W4377029262 hasConceptScore W4377029262C177713679 @default.
- W4377029262 hasConceptScore W4377029262C187212893 @default.
- W4377029262 hasConceptScore W4377029262C2776957806 @default.
- W4377029262 hasConceptScore W4377029262C2779134260 @default.
- W4377029262 hasConceptScore W4377029262C2779416428 @default.
- W4377029262 hasConceptScore W4377029262C2779969927 @default.
- W4377029262 hasConceptScore W4377029262C2910638406 @default.
- W4377029262 hasConceptScore W4377029262C512399662 @default.
- W4377029262 hasConceptScore W4377029262C535046627 @default.
- W4377029262 hasConceptScore W4377029262C61943457 @default.
- W4377029262 hasConceptScore W4377029262C71924100 @default.
- W4377029262 hasConceptScore W4377029262C95457728 @default.
- W4377029262 hasIssue "6" @default.
- W4377029262 hasLocation W43770292621 @default.
- W4377029262 hasOpenAccess W4377029262 @default.
- W4377029262 hasPrimaryLocation W43770292621 @default.
- W4377029262 hasRelatedWork W1974833954 @default.
- W4377029262 hasRelatedWork W2023402573 @default.
- W4377029262 hasRelatedWork W2105924009 @default.
- W4377029262 hasRelatedWork W2224472820 @default.
- W4377029262 hasRelatedWork W2363503150 @default.
- W4377029262 hasRelatedWork W4319459675 @default.
- W4377029262 hasRelatedWork W4322623218 @default.
- W4377029262 hasRelatedWork W4377029262 @default.
- W4377029262 hasRelatedWork W66630131 @default.
- W4377029262 hasRelatedWork W98011991 @default.
- W4377029262 hasVolume "108" @default.
- W4377029262 isParatext "false" @default.
- W4377029262 isRetracted "false" @default.
- W4377029262 workType "article" @default.